At Nimble Therapeutics, we utilize our proprietary light-directed synthesis platform in conjunction with an extensive monomer library to streamline the design, synthesis, and optimization of pharmaceutical molecules tailored to unique disease indications. Our comprehensive portfolio showcases a diverse array of compounds, skillfully engineered from natural and non-natural amino acids, optimized to match target profiles for improved therapeutic outcomes.
Nimble Therapeutics’ proprietary chemical language enables rapid and efficient implementation of design concepts into a set of complete instructions for fully automated, massively parallel library synthesis. These custom-built tools are deeply integrated with our high-precision, fully automated, light-directed chemical synthesis platform. Together, this enables Nimble to design libraries unique to each target and encompassing a chemical space bounded only by imagination.
Explore some design concepts & core implementation of our platform.
Inspired by traditional solid-phase synthesis, Nimble Therapeutics’ proprietary instrumentation represents a sophisticated integration of photolithography, precision optics, fluidics, and automation. Our platform enables exquisite combinatorial synthesis of tailor-made libraries in a matter of hours from up to hundreds of different monomers, in linear cyclic and branched conformations.
Fragment Based Discovery
Protein-Protein Disruptor Discovery
Rapid Phage Single-Step Selection & Step-Wise Array Optimization
Small Branched & Cyclic Peptide Discovery Libraries
Scaffolded alpha helical, beta hairpins Discovery Libraries
Nimble Therapeutics’ veteran team has developed and implemented biological assays for massively parallel screening and optimization of peptides towards molecules with pharmaceutically relevant properties. Our ability to explore and interrogate multiple parameters of molecules in parallel guides downstream modifications harmonized with both the target location and disease.
Our advanced and proprietary analytical pipeline, integrating bioinformatics, chemoinformatics, and machine learning, is engineered from the ground up to transform massive empirical data sets into actionable insights. This purpose-built informatics platform is applied to both de novo library design and subsequent characterization of the resulting empirical data. This process informs creation of the next bespoke library, and fuels a rapid, highly iterative approach to engineering peptides optimized for multiple characteristics in parallel.
OPTIONAL Related Documentation Title Here View PDF
This strategic partnership enables us to broaden the scope of our programs and develop pioneering therapies that can have a profound impact on the lives of millions.
